AHA 2019 The ORION-10 data showed LDL-c lowering of over 50% with inclisiran, which inhibitors production of PCSK9 through RNA interference, with a safety profile similar to placebo.

AHA 2019 This analysis of DAPA-HF shows that dapagliflozin consistently reduced worsening HF events and CV death and improved symptoms in patients with HFrEF, irrespective of diabetes status.

AHA 2019 Daily colchicine lowered ischemic events, mostly urgent revascularization, in patients with an MI less than 30 days ago, in the COLCOT trial. Colchicine was well-tolerated.

AHA 2019 Considering the epidemic of e-cigarette use, particularly among young people, AHA announced substantial investment in research and activities to raise awareness about the risks of vaping.

A study using data of millions of patients showed that there are no differences in effectiveness between drug classes when initiating monotherapy for hypertension, with the exception of lower risk of MI, HHF and stroke with thiazide or thiazide-like diuretics when compared to ACEi.

This observational study showed that women had a higher risk to develop acute HF after STEMI and women with acute HF after STEMI had a higher mortality rate compared to men.

This review comprehensively summarizes both preclinical and clinical data on the CV effects of e-cigarette use. CV effects of e-cigarette constituents as well as of e-cigarette exposure are reviewed. With poll

In a real-world cohort including data of >60,000 AF ablation procedures performed between 2010-2015, early mortality rate was 0.46%. Strongest predictors for early mortality were procedural complications, CHF and low AF ablation hospital volume.

A study of real-world data of 4 large European primary care databases demonstrates that NAFLD is not associated with increased risk of AMI and stroke, after correction for traditional risk factors.

A post hoc analysis of ADVANCE and ADVANCE-ON data shows that a eGFR slope of -3 mL/min/1.73m² was associated with increased risk of clinical outcomes in patients with T2DM.

A randomized clinical trial of hypertensive patients demonstrates that ingestion of hypertension medication at bedtime reduces asleep ABP and CVD event risk compared to ingestion upon awakening.

Exploratory analysis identifies predictors of plaque erosion in patients with ACS who underwent OCT imaging. A combination of non-traditional risk factors can increase the probability of erosion to up to 73%.